BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Ceptaris Therapeutics, Inc. 

3701 Market Street, 4th Floor

Lexington  Kentucky    U.S.A.
Phone: n/a Fax:


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Ceptaris Therapeutics, Inc. Receives FDA Approval for VALCHLOR™ (mechlorethamine) Lymphoma Gel 8/26/2013 6:46:27 AM    More...
Actelion Pharmaceuticals US, Inc. (ATLN.VX) Nabs Ceptaris Therapeutics, Inc. in $250 Million Buyout Deal 8/1/2013 7:14:58 AM    More...
Ceptaris Therapeutics, Inc. Seeking FDA Approval of Drug 3/1/2013 8:25:10 AM    More...
Ceptaris Therapeutics, Inc. Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, the Most Common Type of Cutaneous T-Cell Lymphoma 1/30/2013 9:50:27 AM    More...
Ceptaris Therapeutics, Inc. Secures $10 Million in Series D-1 Financing 6/5/2012 7:36:17 AM    More...
Ceptaris Therapeutics, Inc. Secures $15 Million in Venture Debt Financing 2/21/2012 7:28:38 AM    More...
Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel 1/18/2012 6:52:10 AM    More...
Yaupon Therapeutics Inc. Changes Name to Ceptaris Therapeutics, Inc. 1/5/2012 7:12:14 AM    More...
FDA Accepts Filing of New Drug Application (NDA) for Yaupon Therapeutics Inc.'s Proprietary Gel Formulation of Mechlorethamine Hydrochloride 10/4/2011 8:46:14 AM    More...
Yaupon Therapeutics Inc. Secures $14.4 Million in Series D Financing 8/11/2011 7:19:35 AM    More...
12

//-->